SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...

Mannose-binding lectin (MBL) is a soluble C-type lectin that recognises carbohydrate patterns on a wide range of pathogens and initiates the lectin pathway of complement activation. Upon binding to ...

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

Iptacopan is the first FDA-approved treatment for C3G, targeting the disease's underlying cause by inhibiting the alternative complement pathway. The phase 3 APPEAR-C3G study showed a 35.1% reduction ...